Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicolas James,Philip W. Kantoff,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,Chris Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin +60 more
TLDR
The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.About:
This article is published in European Urology.The article was published on 2018-02-01 and is currently open access. It has received 539 citations till now. The article focuses on the topics: Prostate cancer & Evidence-based medicine.read more
Citations
More filters
Journal ArticleDOI
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman,Michael S Hofman,John Violet,Rodney J. Hicks,Rodney J. Hicks,Justin Ferdinandus,Sue Ping Thang,Tim Akhurst,Tim Akhurst,Amir Iravani,Grace Kong,Aravind S. Ravi Kumar,Declan G. Murphy,Declan G. Murphy,Peter Eu,Price Jackson,Mark Scalzo,Scott Williams,Shahneen Sandhu,Shahneen Sandhu +19 more
TL;DR: The findings show that radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments.
Journal ArticleDOI
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip Cornford,Roderick C.N. van den Bergh,Erik Briers,Thomas Van den Broeck,Marcus G. Cumberbatch,Maria De Santis,Maria De Santis,Stefano Fanti,Nicola Fossati,Giorgio Gandaglia,Silke Gillessen,Nikolaos Grivas,Jeremy Grummet,Ann Henry,Theodorus H. van der Kwast,Thomas B. Lam,Thomas B. Lam,Michael Lardas,Matthew Liew,Malcolm David Mason,Lisa Moris,Daniela E. Oprea-Lager,Henk G. van der Poel,Olivier Rouvière,Ivo G. Schoots,Ivo G. Schoots,Derya Tilki,Thomas Wiegel,Peter-Paul M. Willemse,Nicolas Mottet +29 more
TL;DR: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice and guide the clinician in the discussion with the patient on the treatment decisions to be taken.
Journal ArticleDOI
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi,Neal D. Shore,Teuvo L.J. Tammela,Albertas Ulys,Egils Vjaters,Sergey Polyakov,Mindaugas Jievaltas,M. Luz,Boris Alekseev,Iris Kuss,Christian Kappeler,Amir Snapir,Toni Sarapohja,Matthew R. Smith +13 more
TL;DR: Among men with nonmetastatic, castration‐resistant prostate cancer, metastasis‐free survival was significantly longer with darolutamide than with placebo and was not associated with a higher incidence of seizures, falls, fractures, cognitive disorder, or hypertension than placebo.
Journal ArticleDOI
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S Hofman,Louise Emmett,Shahneen Sandhu,Amir Iravani,Anthony M. Joshua,Jeffrey C. Goh,David A. Pattison,Thean Hsiang Tan,Ian D. Kirkwood,Siobhan Ng,Roslyn J. Francis,Craig Gedye,Natalie Rutherford,Andrew Weickhardt,Andrew M. Scott,Sze Ting Lee,Edmond M. Kwan,Arun Azad,Shakher Ramdave,Andrew Redfern,William Macdonald,Alexander Guminski,Edward C. Hsiao,Wei Chua,Peter Lin,Alison Yan Zhang,Margaret McJannett,Martin R. Stockler,John Violet,Scott Williams,Andrew J. Martin,Ian D. Davis,TheraP Trial Investigators,New Zealand Urogenital +33 more
TL;DR: In this paper, the authors compared Lutetium-177 [177Lu]Lu-PSMA-617 with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi,Nam Phuong Tran,Luis Fein,Nobuaki Matsubara,Alfredo Rodríguez-Antolín,Boris Alekseev,Mustafa Ozguroglu,Dingwei Ye,Susan Feyerabend,Andrew Protheroe,Giri Sulur,Yesenia Luna,Susan Li,Suneel Mundle,Kim N. Chi +14 more
TL;DR: The addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement in overall survival and radiographic progression-free survival compared with placebos plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (mCSPC).
References
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
TL;DR: Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points.
Related Papers (5)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more